JP2004524312A5 - - Google Patents

Download PDF

Info

Publication number
JP2004524312A5
JP2004524312A5 JP2002567898A JP2002567898A JP2004524312A5 JP 2004524312 A5 JP2004524312 A5 JP 2004524312A5 JP 2002567898 A JP2002567898 A JP 2002567898A JP 2002567898 A JP2002567898 A JP 2002567898A JP 2004524312 A5 JP2004524312 A5 JP 2004524312A5
Authority
JP
Japan
Prior art keywords
compound
bond
methyl
compound according
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002567898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524312A (ja
JP4159363B2 (ja
Filing date
Publication date
Priority claimed from US09/794,874 external-priority patent/US6534542B2/en
Application filed filed Critical
Publication of JP2004524312A publication Critical patent/JP2004524312A/ja
Publication of JP2004524312A5 publication Critical patent/JP2004524312A5/ja
Application granted granted Critical
Publication of JP4159363B2 publication Critical patent/JP4159363B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002567898A 2001-02-27 2002-02-19 α２Ｂアドレナリン受容体の調節剤として有用な（２−ヒドロキシ）エチル−チオウレア Expired - Fee Related JP4159363B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/794,874 US6534542B2 (en) 2001-02-27 2001-02-27 (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
PCT/US2002/005021 WO2002068384A2 (en) 2001-02-27 2002-02-19 (2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors

Publications (3)

Publication Number Publication Date
JP2004524312A JP2004524312A (ja) 2004-08-12
JP2004524312A5 true JP2004524312A5 (enExample) 2005-12-22
JP4159363B2 JP4159363B2 (ja) 2008-10-01

Family

ID=25163943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567898A Expired - Fee Related JP4159363B2 (ja) 2001-02-27 2002-02-19 α２Ｂアドレナリン受容体の調節剤として有用な（２−ヒドロキシ）エチル−チオウレア

Country Status (6)

Country Link
US (1) US6534542B2 (enExample)
EP (1) EP1381593A2 (enExample)
JP (1) JP4159363B2 (enExample)
AU (1) AU2002242203B2 (enExample)
CA (1) CA2439838C (enExample)
WO (1) WO2002068384A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
KR20070063016A (ko) * 2004-09-24 2007-06-18 알러간, 인코포레이티드 알파2 아드레날린성 아고니스트로서 작용하는 4-(축합시클릭메틸)-이미다졸-2-티온
JP2008514603A (ja) 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド α２アドレナリン作動剤としての４−（ヘテロアリール−メチルおよび置換ヘテロアリール−メチル）−イミダゾール−２−チオン
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008014299A2 (en) * 2006-07-27 2008-01-31 Allergan, Inc. Use of an alpha2-agonist composition for the treatment of hyperlipidemia
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20100016355A1 (en) 2006-12-22 2010-01-21 Gil Daniel W Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2011028621A1 (en) 2009-08-26 2011-03-10 Allergan, Inc. Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
DK2605771T3 (en) 2010-08-16 2018-07-16 Allergan Inc PROCEDURE FOR ACTIVATING REGULATORY T CELLS WITH ALPHA-2B-ADDRENGE RECEPTOR AGONISTS
CN109336917A (zh) * 2013-06-04 2019-02-15 塞勒创尼克斯公司 腈-取代的硅烷和电解质组合物和包含它们的电化学装置
CN105531252B (zh) 2013-09-12 2018-01-09 信越化学工业株式会社 用于制备β‑环薰衣草醛及其衍生物的方法
WO2015037664A1 (ja) * 2013-09-12 2015-03-19 信越化学工業株式会社 シクロラバンジュロール及びその誘導体の製造方法
RU2552529C1 (ru) * 2013-11-29 2015-06-10 Федеральное государственное бюджетное учреждение "Медицинский радиологический научный центр" Министерства здравоохранения Российской Федерации (ФГБУ МРНЦ Минздрава России) Вазопрессорное средство
US12440821B2 (en) 2021-12-13 2025-10-14 Saudi Arabian Oil Company Method for tracing subterranean formations with oil-soluble organic molecular tracers and extracting them of from oil phases
US11725139B2 (en) 2021-12-13 2023-08-15 Saudi Arabian Oil Company Manipulating hydrophilicity of conventional dye molecules for water tracer applications
US12188350B2 (en) * 2022-06-08 2025-01-07 Saudi Arabian Oil Company Fluorescent dye oil tracer compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2161772A (en) * 1936-04-17 1939-06-06 Monsanto Chemicals Phenol stabilization
US3686303A (en) * 1967-04-20 1972-08-22 Du Pont Certain substituted cyclohexyl ureas and thioureas
SU795462A3 (ru) 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US5212176A (en) 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Similar Documents

Publication Publication Date Title
JP2004524312A5 (enExample)
CA2439838A1 (en) (2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors
JP2009528375A5 (enExample)
JP2004526788A5 (enExample)
TWI598098B (zh) 脂質異常症治療劑
JP2009531280A5 (enExample)
JP2004505947A5 (enExample)
JP2007512376A5 (enExample)
JP2002533472A5 (enExample)
RU2000132188A (ru) Производные эпотилонов, их синтез и применение
JP2004526745A5 (enExample)
RU2003100076A (ru) Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х
JP2010514831A5 (enExample)
JPWO2020123827A5 (enExample)
JP2003509349A5 (enExample)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2007530694A5 (enExample)
JP2002519425A5 (enExample)
JP2005512965A5 (enExample)
JP2005508337A5 (enExample)
JP2020111571A5 (enExample)
RU2002101622A (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
JP2002544227A5 (enExample)
JP2004525905A5 (enExample)
JPH1036365A5 (enExample)